AU2017275782B2 - A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer - Google Patents

A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Download PDF

Info

Publication number
AU2017275782B2
AU2017275782B2 AU2017275782A AU2017275782A AU2017275782B2 AU 2017275782 B2 AU2017275782 B2 AU 2017275782B2 AU 2017275782 A AU2017275782 A AU 2017275782A AU 2017275782 A AU2017275782 A AU 2017275782A AU 2017275782 B2 AU2017275782 B2 AU 2017275782B2
Authority
AU
Australia
Prior art keywords
seq
polypeptide
sequence
cancer
immune checkpoint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017275782A
Other languages
English (en)
Other versions
AU2017275782A1 (en
Inventor
Gustav Gaudernack
Audun Tornes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ultimovacs ASA
Original Assignee
Ultimovacs ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultimovacs ASA filed Critical Ultimovacs ASA
Publication of AU2017275782A1 publication Critical patent/AU2017275782A1/en
Application granted granted Critical
Publication of AU2017275782B2 publication Critical patent/AU2017275782B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017275782A 2016-06-02 2017-06-02 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer Ceased AU2017275782B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16172760 2016-06-02
EP16172760.7 2016-06-02
PCT/EP2017/063589 WO2017207814A1 (en) 2016-06-02 2017-06-02 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer

Publications (2)

Publication Number Publication Date
AU2017275782A1 AU2017275782A1 (en) 2019-01-24
AU2017275782B2 true AU2017275782B2 (en) 2024-08-15

Family

ID=56132759

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017275782A Ceased AU2017275782B2 (en) 2016-06-02 2017-06-02 A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer

Country Status (16)

Country Link
US (2) US11419927B2 (cg-RX-API-DMAC7.html)
EP (2) EP4253419A3 (cg-RX-API-DMAC7.html)
JP (2) JP7321709B2 (cg-RX-API-DMAC7.html)
AU (1) AU2017275782B2 (cg-RX-API-DMAC7.html)
CA (1) CA3026172A1 (cg-RX-API-DMAC7.html)
DK (1) DK3463436T3 (cg-RX-API-DMAC7.html)
ES (1) ES2965957T3 (cg-RX-API-DMAC7.html)
FI (1) FI3463436T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231650T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065176T2 (cg-RX-API-DMAC7.html)
LT (1) LT3463436T (cg-RX-API-DMAC7.html)
PL (1) PL3463436T3 (cg-RX-API-DMAC7.html)
PT (1) PT3463436T (cg-RX-API-DMAC7.html)
RS (1) RS65007B1 (cg-RX-API-DMAC7.html)
SI (1) SI3463436T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017207814A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3581649A1 (en) 2010-02-16 2019-12-18 Ultimovacs ASA Polypeptides
HUE065176T2 (hu) 2016-06-02 2024-05-28 Ultimovacs Asa Vakcina kombinációban immunellenõrzõpont inhibitorral felhasználásra rák kezelésében
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
US12251447B2 (en) 2018-06-29 2025-03-18 Taiho Pharmaceutical Co., Ltd. Combined formulation comprising four linked cytotoxic T lymphocyte (CTL) epitopes and a PD-1 pathway inhibitor and methods of use thereof to treat cancer
WO2022258794A2 (en) 2021-06-09 2022-12-15 Ultimovacs Ab A conjugate
WO2024083867A1 (en) 2022-10-17 2024-04-25 Ultimovacs Asa Biomarker
WO2024126758A2 (en) 2022-12-14 2024-06-20 Ultimovacs Ab A nucleic acid molecule and a chimeric polypeptide
WO2024126737A1 (en) 2022-12-14 2024-06-20 Ultimovacs Ab A core and a conjugate

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148021A0 (en) 1999-08-23 2002-09-12 Dana Farber Cancer Inst Inc Novel b7-4 molecules and uses therefor
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
WO2003086459A1 (en) 2002-04-12 2003-10-23 Medarex, Inc. Methods of treatement using ctla-4 antibodies
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
EP3581649A1 (en) 2010-02-16 2019-12-18 Ultimovacs ASA Polypeptides
US9522962B2 (en) 2010-03-15 2016-12-20 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Peptides, conjugates and method for increasing immunogenicity of a vaccine
WO2012037551A2 (en) 2010-09-17 2012-03-22 Irx Therapeutics, Inc. Primary cell-derived biologic and wt1 synthetic long peptide vaccine
WO2014036562A2 (en) 2012-08-31 2014-03-06 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
GB201223386D0 (en) 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
SG10201710472PA (en) 2013-02-22 2018-02-27 Curevac Ag Combination of vaccination and inhibition of the pd-1 pathway
EA201992251A1 (ru) 2013-03-15 2020-05-08 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Противораковые вакцины и способы лечения с их применением
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
JP2017500313A (ja) 2013-12-09 2017-01-05 ブレット バイオテクノロジー， インコーポレーテッドＢｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 特異的ウイルス様粒子−ＣｐＧオリゴヌクレオチドワクチンおよびその使用
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
US9903102B2 (en) 2013-12-27 2018-02-27 Xiamen Solex High-Tech Industries Co., Ltd. Concealed embedded component for a waterway system
EP3542816A1 (en) 2014-02-14 2019-09-25 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
WO2015128313A1 (en) 2014-02-25 2015-09-03 Deutsches Krebsforschungszentrum Rna viruses for immunovirotherapy
AU2015259516B2 (en) 2014-05-13 2020-05-28 Bavarian Nordic A/S Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against TIM-3
US20170266270A1 (en) 2014-05-13 2017-09-21 Bavarian Nordic A/S Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor
WO2016004213A2 (en) 2014-07-01 2016-01-07 Vicus Therapeutics, Llc Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them
EP3166646A4 (en) 2014-07-07 2018-03-07 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
EP3166630A4 (en) 2014-07-07 2018-03-28 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
WO2016011362A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Listeria-based immunogenic compositions for eliciting anti-tumor responses
CN106715458A (zh) 2014-07-18 2017-05-24 华盛顿大学 癌症疫苗组合物及其使用方法
US20170224777A1 (en) 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
IL251844B2 (en) 2014-10-23 2024-04-01 Roussy Inst Gustave Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
EP3215182B1 (en) 2014-11-05 2023-01-04 The Regents of The University of California Combination immunotherapy
CA2954892A1 (en) 2016-01-19 2017-07-19 Pfizer Inc. Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens
HUE065176T2 (hu) 2016-06-02 2024-05-28 Ultimovacs Asa Vakcina kombinációban immunellenõrzõpont inhibitorral felhasználásra rák kezelésében
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies

Also Published As

Publication number Publication date
JP7321709B2 (ja) 2023-08-07
JP2019517508A (ja) 2019-06-24
WO2017207814A1 (en) 2017-12-07
ES2965957T3 (es) 2024-04-17
EP3463436A1 (en) 2019-04-10
FI3463436T3 (fi) 2023-12-04
RS65007B1 (sr) 2024-01-31
EP3463436B1 (en) 2023-09-20
SI3463436T1 (sl) 2024-02-29
US11419927B2 (en) 2022-08-23
JP2022171684A (ja) 2022-11-11
DK3463436T3 (da) 2023-12-18
HUE065176T2 (hu) 2024-05-28
EP4253419A3 (en) 2024-05-22
LT3463436T (lt) 2024-01-25
HRP20231650T1 (hr) 2024-05-10
US12168045B2 (en) 2024-12-17
CA3026172A1 (en) 2017-12-07
PL3463436T3 (pl) 2024-03-04
AU2017275782A1 (en) 2019-01-24
EP4253419A2 (en) 2023-10-04
US20230049012A1 (en) 2023-02-16
PT3463436T (pt) 2023-12-28
US20190247482A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
US12168045B2 (en) Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
US11998595B2 (en) Telomerase polypeptide vaccine for treating cancer
US20230414735A1 (en) Neoantigens and methods of their use
KR102823333B1 (ko) 암 치료 방법 및 조성물
CN111093691A (zh) 蛋白质抗原及其用途
RS53872B1 (sr) Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
Agarwal et al. Development of novel immune interventions for prostate cancer
WO2001011044A1 (fr) Antigene de tumeur
TW201106962A (en) CDC45L peptides and vaccines including the same
US20060045884A1 (en) Vaccines for autoimmune and infectious disease
WO2024083866A1 (en) Cancer treatment
Thomas Development of a prostatic acid phosphatase-derived vaccine for the treatment of advanced prostate cancer
RU2773273C2 (ru) Неоантигены и способы их использования
KR20220010712A (ko) Wt1-양성 암을 치료하기 위한 다가 면역요법 조성물 및 사용 방법
HK40029579A (en) Protein antigens and uses thereof
HK1177762A (en) Polypeptides
HK1177762B (en) Polypeptides
HK40004257A (en) Neoantigens and methods of their use
HK1242735B (en) Cdc45l peptides and vaccines including the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)